A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Phase 1 Completed 14 enrolled Amgen

NaSingle-groupOpen-labelBasic science

Summary

The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either famotidine or omeprazole in healthy participants under fed conditions.

Timeline

Start: 2020-07-17
Primary completion: 2020-09-13
Completion: 2020-09-13

Publications

Cardona P, Strydom N, Houk B. Impact of Acid-Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic Beverage. Clin Pharmacol Drug Dev. 2025 Feb;14(2):167-176. doi: 10.1002/cpdd.1489. Epub 2024 Nov 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Famotidine	Other / unclassified	—	—
Subject	Omeprazole	Other / unclassified	—	—
Subject	Sotorasib	Small molecule	—	Oral

Indications

No indication recorded.